<SEC-DOCUMENT>0001683168-24-002961.txt : 20240503
<SEC-HEADER>0001683168-24-002961.hdr.sgml : 20240503
<ACCEPTANCE-DATETIME>20240503162618
ACCESSION NUMBER:		0001683168-24-002961
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240430
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240503
DATE AS OF CHANGE:		20240503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CNS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001729427
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				822318545
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39126
		FILM NUMBER:		24913567

	BUSINESS ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		1-800-946-9185

	MAIL ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cns_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CNSP="http://cnspharma.com/20240430">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_CNSP_cnspharma.com_20240430 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20240430_20240430 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001729427 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000005" name="dei:EntityCentralIndexKey">0001729427</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cnsp-20240430.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001729427</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-30</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20240430__20240430_zl92NRGNQfF3"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_903_edei--DocumentPeriodEndDate_c20240430__20240430_zKWjQcicczvb"> <ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">April
30, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20240430__20240430_zjR1lXcM4yF5"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000012" name="dei:EntityRegistrantName">CNS Pharmaceuticals, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20240430__20240430_zpUI8F7CUMug"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20240430__20240430_z4mFttw8M3M8"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000014" name="dei:EntityFileNumber">001-39126</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20240430__20240430_zsNXjWeITOzc"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000015" name="dei:EntityTaxIdentificationNumber">82-2318545</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</p></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20240430__20240430_zqBbapQFhTxa"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000016" name="dei:EntityAddressAddressLine1">2100 West Loop South</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20240430__20240430_zFAKbmGl9bHh"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite 900</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20240430__20240430_zksmcTlhEbJ4"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000018" name="dei:EntityAddressCityOrTown">Houston</ix:nonNumeric></span>,
<span id="xdx_90F_edei--EntityAddressStateOrProvince_c20240430__20240430_zeaYi6zWcuJ2"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20240430__20240430_zktLYf46aSK4"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000020" name="dei:EntityAddressPostalZipCode">77027</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">(Address of principal executive offices)
(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: <span id="xdx_903_edei--CityAreaCode_c20240430__20240430_za3vrzjZcw93"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000021" name="dei:CityAreaCode">(800)</ix:nonNumeric></span> <span id="xdx_90A_edei--LocalPhoneNumber_c20240430__20240430_zWHTu9B5Bdx9"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000022" name="dei:LocalPhoneNumber">946-9185</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see </i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--WrittenCommunications_c20240430__20240430_zCcAKmhsSfZ1"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--SolicitingMaterial_c20240430__20240430_z73Q157UYJE1"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20240430__20240430_zB4UsQHfIfQl"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20240430__20240430_zFR64gIkuZsa"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: right">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20240430__20240430_zPa9cGdyTyGe"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt:booleantrue" id="Fact000027" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160; <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityExTransitionPeriod_c20240430__20240430_zW20D9m5IGYg"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; padding-left: 0pt; width: 40%; text-align: justify"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 20%; text-align: justify"><span style="font-size: 10pt">Trading Symbols(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 40%; text-align: justify"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20240430__20240430_zpN3WAhF5rA3"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000029" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20240430__20240430_zebzVKIQmjM7"><ix:nonNumeric contextRef="AsOf2024-04-30" id="Fact000030" name="dei:TradingSymbol">CNSP</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 10pt">The <span id="xdx_908_edei--SecurityExchangeName_c20240430__20240430_zEpUqAfebEcl"><ix:nonNumeric contextRef="AsOf2024-04-30" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in; text-align: left"><b>Item 5.02</b></td><td style="text-align: justify"><b>Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reported below under Item 5.07 of this Current
Report, CNS Pharmaceuticals, Inc. (the &#8220;Company&#8221;) held its scheduled 2024 Annual Meeting of Stockholders (the &#8220;Annual
Meeting&#8221;) at which the Company&#8217;s stockholders approved amendments to the Company's 2020 Equity Plan (the &#8220;2020 Plan&#8221;)
including an increase in the number of shares of common stock, par value $0.001 per share, authorized for issuance under the 2020 Plan
by 3,500,000 shares. As amended, the number of shares of the common stock that may be issued under the 2020 Plan is 4,345,800 shares (this
includes the 3,500,000 share increase).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information about the 2020 Plan and amendments
thereto, see the Company&#8217;s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 10, 2024 (the
&#8220;Proxy Statement&#8221;), the relevant portions of which are incorporated herein by reference. The foregoing description of the
amendments to the 2020 Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the
2020 Plan, as amended, a copy of which is filed as Exhibit 10.1 to this Current Report and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 30, 2024, the Board of Directors of the Company approved the
following appointments to its Board committees: (i) Audit Committee &#8211; Jeff Keyes (Chair), Faith Charles and Amy Mahery; (ii) Compensation
Committee &#8211; Dr. Jerzy (George) Gumulka (Chair), Amy Mahery and Dr. Bettina Cockroft; and (iii) Nominating and Governance Committee
&#8211; Dr. Bettina Cockroft (Chair) and Faith Charles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in; text-align: left"><b>Item 5.03</b></td><td style="text-align: justify"><b>Amendments to Articles of Incorporation or Bylaws; Change in
Fiscal Year.</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reported below under Item 5.07 of this Current
Report, the Company held its Annual Meeting on April 30, 2024, at which the Company&#8217;s stockholders approved an amendment to the
Company&#8217;s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from
75,000,000 shares to 300,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2024, the Company filed a Certificate
of Amendment to its Amended and Restated Articles of Incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State
of Nevada to&#160;increase&#160;the&#160;number&#160;of&#160;the Company&#8217;s authorized shares of common stock from 75,000,000 shares
to 300,000,000 shares. A copy of the Amendment is filed as Exhibit 3.1 to this Current Report and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information about the Amendment, see
the Proxy Statement, the relevant portions of which are incorporated herein by reference. The information set forth herein is qualified
in its entirety by reference to the complete text of the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report and
is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in; text-align: left"><b>Item 5.07</b></td><td style="text-align: justify"><b>Submission of Matters to a Vote of Security Holders.</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company held its Annual Meeting as a virtual
meeting online via live audio webcast on Tuesday, April 30, 2024, at 3:00 p.m. Eastern Time. As of March 21, 2024, the record date for
the Annual Meeting, there were 10,634,932 shares of common stock issued and outstanding and entitled to vote on the proposals presented
at the Annual Meeting, of which 7,438,115, or 69.94%, were present in person or represented by proxy, which constituted a quorum. The
holders of shares of Company common stock are entitled to one vote for each share held. Set forth below are the final voting results for
each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposals are described in detail in the Proxy
Statement, the relevant portions of which are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal 1. Election of Directors</b> - The
Company&#8217;s stockholders elected John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Faith Charles, Bettina Cockroft, and Amy Mahery,
each to serve until the 2025 Annual Meeting of Stockholders or until such person&#8217;s successor is qualified and elected, by the following
vote:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Director Name</td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Votes For</td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Against</td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Abstain</td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Broker Non-Votes</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 32%; text-align: left">John Climaco</td><td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: center">2,806,862</td><td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: center">419,414</td><td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: center">10,728</td><td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: center">4,326,111</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Jerzy (George) Gumulka</td><td>&#160;</td>
    <td style="text-align: center">2,530,498</td><td>&#160;</td>
    <td style="text-align: center">688,740</td><td>&#160;</td>
    <td style="text-align: center">17,766</td><td>&#160;</td>
    <td style="text-align: center">4,326,111</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Jeffry R. Keyes</td><td>&#160;</td>
    <td style="text-align: center">2,737,164</td><td>&#160;</td>
    <td style="text-align: center">479,314</td><td>&#160;</td>
    <td style="text-align: center">20,526</td><td>&#160;</td>
    <td style="text-align: center">4,326,111</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Faith Charles</td><td>&#160;</td>
    <td style="text-align: center">2,836,539</td><td>&#160;</td>
    <td style="text-align: center">386,803</td><td>&#160;</td>
    <td style="text-align: center">13,662</td><td>&#160;</td>
    <td style="text-align: center">4,326,111</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Bettina Cockroft</td><td>&#160;</td>
    <td style="text-align: center">2,878,946</td><td>&#160;</td>
    <td style="text-align: center">337,556</td><td>&#160;</td>
    <td style="text-align: center">20,502</td><td>&#160;</td>
    <td style="text-align: center">4,326,111</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amy Mahery</td><td>&#160;</td>
    <td style="text-align: center">2,951,391</td><td>&#160;</td>
    <td style="text-align: center">272,219</td><td>&#160;</td>
    <td style="text-align: center">13,394</td><td>&#160;</td>
    <td style="text-align: center">4,326,111</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal 2. Ratification of Appointment of
Independent Registered Public Accounting Firm - </b>The Company's stockholders ratified the appointment of MaloneBailey, LLP as the Company's
independent registered public accounting firm for the year ending December 31, 2024, by the following vote:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes For</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes Against</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">6,880,698</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">439,554</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">117,863</span></td>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal 3. Reverse Split Authorization Approval&#160;&#8211;</b>
The Company&#8217;s stockholders granted the Company&#8217;s Board of Directors authority, in its sole discretion, prior to the one-year
anniversary of the Annual Meeting, to effect a reverse stock split of the outstanding shares of the Company&#8217;s common stock, at a
reverse split ratio of between 1-for-2 and 1-for-50 as determined by the Board of Directors, by the filing of an amendment to the Company's
Amended and Restated Articles of Incorporation, by the following vote:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes For</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes Against</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">5,879,954</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1,672,316</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">10,845</span></td>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal 4. Amendment to Articles of Incorporation
Approval - </b>The Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Articles of Incorporation
to increase the total number of authorized shares of common stock from 75,000,000 shares to 300,000,000 shares, by the following vote:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes For</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes Against</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">5,419,397</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2,075,496</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">68,222</span></td>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal 5. Amendment to 2020 Stock Plan
Approval - </b>The Company&#8217;s stockholders approved amendments to the Company's 2020 Equity Plan including an increase in the number
of shares of common stock authorized for issuance under the 2020 Plan, by the following vote:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes For</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes Against</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2,471,451</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">591,602</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">173,951</span></td>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">4,326,111</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal 6. Nasdaq Listing Rule 5635(d)
Approval </b>- For purposes of complying with Nasdaq Listing Rule 5635(d), the Company&#8217;s stockholders approved the repricing of
certain warrants to purchase up to 3,756,000 shares of common stock issued on October 16, 2023 (the &#8220;October 2023 Warrants&#8221;),
from $1.28 per share to $0.30 per share and to extend the termination date of such warrants to February 1, 2029 (collectively, the &#8220;Nasdaq
Proposal&#8221;), by the following vote:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes For</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes Against</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2,573,758</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">644,291</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">18,955</span></td>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">4,326,111</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal 7. To Authorize an Adjournment
of the Annual Meeting - </b>The Company&#8217;s stockholders authorized the adjournment of the Annual Meeting, if necessary, to solicit
additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve
any of the above proposals, by the following vote:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes For</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Votes Against</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 25%"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">6,099,275</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1,206,455</span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">257,385</span></td>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 9.01.</b></td><td><b>Financial Statements and Exhibits</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 2%">&#160;</td>
    <td style="width: 11%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 87%"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.1</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="cns_0301.htm">Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada</a></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="cns_1001.htm">CNS Pharmaceuticals, Inc. 2020 Equity Plan (as amended April 30, 2024)</a></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Signature</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc.</p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    <td style="width: 11%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt"><span style="text-decoration: underline">/s/ Chris
    Downs&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chris Downs</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Dated: May 3, 2024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZi43Rbrq0qIhVpBRxG+xUgm2mTOLfkbylaYs4DAzDe997QkzEhtamQYbzssihxLZrtEcosEZGe8HgyLa7FMIt8GqcZ2398P7AjAKDgUmmSukgDNaHcVilIJNYqlgtQKpUzeG4F1GvZ2RrU6H1RjegbQVHpo4Nes3vMaHUL7LUvoeqE7IzZFOYTeUof0DJmYIDPfST+OYgzzMRTYaJxIbp3gXX6uXR9iSsGmxDnRvp/0ZfAqBKhg== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>cns_0301.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF CNS PHARMACEUTICALS, INC., FILED WITH THE SECRETARY OF STATE OF THE STATE OF NEVADA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TEXT OF CERTIFICATE OF AMENDMENT&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION
OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CNS PHARMACEUTICALS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.1 of the Amended
and Restated Articles of Incorporation is amended and restated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1. The Corporation shall
have the authority to issue 300,000,000 shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="margin: 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>cns_1001.htm
<DESCRIPTION>CNS PHARMACEUTICALS, INC. 2020 EQUITY PLAN (AS AMENDED APRIL 30, 2024)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exhibit 10.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CNS PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020 EQUITY PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Amended and Restated)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>______________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Establishment and Purpose.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">1.1</FONT>The
Board of Directors of CNS Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) established the CNS Pharmaceuticals, Inc. 2020 Equity Plan
(the &ldquo;Plan&rdquo;) effective as of April 6, 2020, which was approved by the Company&rsquo;s stockholders at the Company&rsquo;s
annual meeting on June 8, 2020. The Plan was amended effective as of August 9, 2023, and on March 26, 2024, subject to approval by the
Company&rsquo;s stockholders at the Company&rsquo;s annual meeting on April 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">1.2</FONT>The
purpose of the Plan is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its
Subsidiaries, to recognize the contributions made to the Company and its Subsidiaries by Key Employees, Directors and Consultants, and
to provide such Key Employees, Directors and Consultants with additional incentive to expand and improve the profits and achieve the objectives
of the Company and its Subsidiaries, by providing such Key Employees, Directors and Consultants with the opportunity to acquire or increase
their proprietary interest in the Company through receipt of Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Definitions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in the Plan, the following
terms shall have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.1</FONT><U>&ldquo;Award&rdquo;</U>
means any award or benefit granted under the Plan, which shall be a Stock Option, a Stock Award, a Stock Unit Award or an SAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.2</FONT><U>&ldquo;Award
Agreement&rdquo;</U> means, as applicable, a Stock Option Agreement, Stock Award Agreement, Stock Unit Award Agreement or SAR Agreement
evidencing an Award granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.3</FONT><U>&ldquo;Board&rdquo;</U>
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.4</FONT><U>&ldquo;Change
in Control&rdquo;</U> has the meaning set forth in Section 8.2 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.5</FONT><U>&ldquo;Code&rdquo;</U>
means the Internal Revenue Code of 1986, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.6</FONT><U>&ldquo;Committee&rdquo;</U>
means the Compensation Committee of the Board or such other committee as may be designated by the Board from time to time to administer
the Plan, or, if no such committee has been designated at the time of any grants, it shall mean the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.7</FONT><U>&ldquo;Common
Stock&rdquo;</U> means the Common Stock, par value $0.001 per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.8</FONT><U>&ldquo;Company&rdquo;</U>
means CNS Pharmaceuticals, Inc., a Nevada corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.9</FONT><U>&ldquo;Consultant&rdquo;</U>
means any person, including an advisor, who is engaged by the Company or an affiliate to render consulting or advisory services and is
compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director
to be considered a &ldquo;Consultant&rdquo; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant
under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale
of the Company&rsquo;s securities to such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.10</FONT><U>&ldquo;Director&rdquo;</U>
means a director of the Company who is not an employee of the Company or a Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.11</FONT><U>&ldquo;Exchange
Act&rdquo;</U> means the Securities Exchange Act of 1934, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.12</FONT><U>&ldquo;Fair
Market Value&rdquo;</U> means as of any date, the closing price of a share of Common Stock on the national securities exchange on which
the Common Stock is listed, or, if the Common Stock is not listed on a national securities exchange, the over-the-counter market on which
the Common Stock trades, or, if the Common Stock is not listed on a national securities exchange or an over-the-counter market, as determined
by the Board as of such date, or, if no trading occurred on such date, as of the trading day immediately preceding such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.13</FONT><U>&ldquo;Incentive
Stock Option&rdquo;</U> or &ldquo;<U>ISO&rdquo;</U> means a Stock Option granted under Section 5 of the Plan that meets the requirements
of Section 422(b) of the Code or any successor provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.14</FONT><U>&ldquo;Key
Employee&rdquo;</U> means an employee of the Company or any Subsidiary selected to participate in the Plan in accordance with Section
3. A Key Employee may also include a person who is granted an Award (other than an Incentive Stock Option) in connection with the hiring
of the person prior to the date the person becomes an employee of the Company or any Subsidiary, provided that such Award shall not vest
prior to the commencement of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.15</FONT><U>&ldquo;Non-Qualified
Stock Option&rdquo;</U> or <U>&ldquo;NSO&rdquo;</U> means a Stock Option granted under Section 5 of the Plan that is not an Incentive
Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.16</FONT>&ldquo;<U>Participant&rdquo;</U>
means a Key Employee, Director or Consultant selected to receive an Award under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.17</FONT>&ldquo;<U>Plan&rdquo;</U>
means the CNS Pharmaceuticals, Inc. 2020 Equity Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.18</FONT>&ldquo;<U>Stock
Appreciation Right&rdquo;</U> or &ldquo;<U>SAR&rdquo;</U> means a grant of a right to receive shares of Common Stock or cash under Section
8 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.19</FONT>&ldquo;<U>Stock
Award&rdquo;</U> means a grant of shares of Common Stock under Section 6 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.20</FONT>&ldquo;<U>Stock
Option&rdquo;</U> means an Incentive Stock Option or a Non-Qualified Stock Option granted under Section 5 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.21</FONT>&ldquo;<U>Stock
Unit Award&rdquo;</U> means a grant of a right to receive shares of Common Stock or cash under Section 7 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.22</FONT>&ldquo;<U>Subsidiary&rdquo;</U>
means an entity of which the Company is the direct or indirect beneficial owner of not less than 50% of all issued and outstanding equity
interest of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Administration.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.1</FONT><U>The
Committee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan shall be administered
by the Committee, which shall be comprised of at least two members of the Board who satisfy the &ldquo;non-employee director&rdquo; definition
set forth in Rule 16b-3 under the Exchange Act, unless the Board otherwise determines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.2</FONT><U>Authority
of the Committee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Committee, in its sole discretion, shall determine the Key Employees, Consultants and Directors to whom, and the time or times
at which Awards will be granted, the form and amount of each Award, the expiration date of each Award, the time or times within which
the Awards may be exercised, the cancellation of the Awards and the other limitations, restrictions, terms and conditions applicable to
the grant of the Awards. The terms and conditions of the Awards need not be the same with respect to each Participant or with respect
to each Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>To the extent permitted by applicable law, regulation, and rules of a stock exchange on which the Common Stock is listed or traded,
the Committee may delegate its authority to grant Awards to Key Employees and to determine the terms and conditions thereof to such officer
of the Company as it may determine in its discretion, on such terms and conditions as it may impose, except with respect to Awards to
officers subject to Section 16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Committee may, subject to the provisions of the Plan, establish such rules and regulations as it deems necessary or advisable
for the proper administration of the Plan, and may make determinations and may take such other action in connection with or in relation
to the Plan as it deems necessary or advisable. Each determination or other action made or taken pursuant to the Plan, including interpretation
of the Plan and the specific terms and conditions of the Awards granted hereunder, shall be final and conclusive for all purposes and
upon all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>No member of the Board or the Committee shall be liable for any action taken or determination made hereunder in good faith. Service
on the Committee shall constitute service as a Director so that the members of the Committee shall be entitled to indemnification and
reimbursement as Directors of the Company pursuant to the Company&rsquo;s Amended and Restated Articles of Incorporation and Amended and
Restated Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.3</FONT><U>Award
Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Each Award shall be evidenced by a written Award Agreement specifying the terms and conditions of the Award. In the sole discretion
of the Committee, the Award Agreement may condition the grant of an Award upon the Participant&rsquo;s entering into one or more of the
following agreements with the Company: (i) an agreement not to compete with the Company and its Subsidiaries which shall become effective
as of the date of the grant of the Award and remain in effect for a specified period of time following termination of the Participant&rsquo;s
employment with the Company; (ii) an agreement to cancel any employment agreement, fringe benefit or compensation arrangement in effect
between the Company and the Participant; and (iii) an agreement to retain the confidentiality of certain information. Such agreements
may contain such other terms and conditions as the Committee shall determine. If the Participant shall fail to enter into any such agreement
at the request of the Committee, then the Award granted or to be granted to such Participant shall be forfeited and cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Shares of Common Stock Subject to Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.1</FONT><U>Total
Number of Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The total number of shares of Common Stock that may be issued under the Plan shall be 4,345,800 (which reflects the 845,800 shares
previously authorized under the Plan and 3,500,000 shares to be issued under the Plan pursuant to this amendment and restatement). Such
shares may be either authorized but unissued shares or treasury shares, and shall be adjusted in accordance with the provisions of Section
4.3 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The number of shares of Common Stock delivered by a Participant or withheld by the Company on behalf of any such Participant as
full or partial payment of an Award, including the exercise price of a Stock Option or of any required withholding taxes, shall not again
be available for issuance pursuant to subsequent Awards, and shall count towards the aggregate number of shares of Common Stock that may
be issued under the Plan. Any shares of Common Stock purchased by the Company with proceeds from a Stock Option exercise shall not again
be available for issuance pursuant to subsequent Awards, shall count against the aggregate number of shares that may be issued under the
Plan and shall not increase the number of shares available under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>If there is a lapse, forfeiture, expiration, termination or cancellation of any Award for any reason (including for reasons described
in Section 3.3), or if shares of Common Stock are issued under such Award and thereafter are reacquired by the Company pursuant to rights
reserved by the Company upon issuance thereof, the shares of Common Stock subject to such Award or reacquired by the Company shall again
be available for issuance pursuant to subsequent Awards, and shall not count towards the aggregate number of shares of Common Stock that
may be issued under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.2</FONT><U>Shares
Under Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of the shares of Common Stock
authorized for issuance under the Plan pursuant to Section 4.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The maximum number of shares of Common Stock as to which a Key Employee may receive Stock Options or SARs in any calendar year
will not exceed $1,500,000 in total value (calculating the value of any such Stock Options or SARs based on the grant date fair value
of such Stock Options or SARs for financial reporting purposes). For the avoidance of doubt, shares of Common Stock that may be used for
Stock Awards and/or Stock Unit Awards pursuant to Section 4.2(c) shall not be included in the foregoing calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The maximum number of shares of Common Stock that may be subject to Stock Options (ISOs and/or NSOs) is the total number of shares
set forth in Section 4.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The maximum number of shares of Common Stock that may be used for Stock Awards and/or Stock Unit Awards that may be granted to
any Key Employee in any calendar year will not exceed $1,500,000 in total value (calculating the value of any such Stock Awards and/or
Stock Unit Awards based on the grant date fair value of such Stock Awards and/or Stock Unit Awards for financial reporting purposes).
For the avoidance of doubt, shares of Common Stock that may be used for Stock Options and/or SARs pursuant to Section 4.2(a) shall not
be included in the foregoing calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The maximum number of shares of Common Stock subject to Awards granted under the Plan or otherwise during any one calendar year
to any Director, taken together with any cash fees paid by the Company to such Director during such calendar year for service on the Board,
will not exceed $300,000 in total value (calculating the value of any such Awards based on the grant date fair value of such Awards for
financial reporting purposes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The numbers of shares described herein shall be
as adjusted in accordance with Section 4.3 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.3</FONT><U>Adjustment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any reorganization,
recapitalization, stock split, stock distribution, merger, consolidation, split-up, spin-off, combination, subdivision, consolidation
or exchange of shares, any change in the capital structure of the Company or any similar corporate transaction, the Committee shall make
such adjustments as it deems appropriate, in its sole discretion, to preserve the benefits or intended benefits of the Plan and Awards
granted under the Plan. Such adjustments may include: (a) adjustment in the number and kind of shares reserved for issuance under the
Plan; (b) adjustment in the number and kind of shares covered by outstanding Awards; (c) adjustment in the exercise price of outstanding
Stock Options or SARs or the price of Stock Awards or Stock Unit Awards under the Plan; (d) adjustments to any of the shares limitations
set forth in Section 4.1 or 4.2 of the Plan; and (e) any other changes that the Committee determines to be equitable under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 5.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Grants of Stock Options.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.1</FONT><U>Grant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
Plan, the Committee may from time to time grant Stock Options to Participants. Unless otherwise expressly provided at the time of the
grant, Stock Options granted under the Plan to Key Employees will be NSOs. Stock Options granted under the Plan to Directors or Consultants
who, in each case are not employees of the Company or any Subsidiary will be NSOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.2</FONT><U>Stock
Option Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The grant of each Stock Option
shall be evidenced by a written Stock Option Agreement specifying the type of Stock Option granted, the exercise period, the exercise
price, the terms for payment of the exercise price, the expiration date of the Stock Option, the number of shares of Common Stock to be
subject to each Stock Option and such other terms and conditions established by the Committee, in its sole discretion, not inconsistent
with the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.3</FONT><U>Exercise
Price and Exercise Period</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to each Stock
Option granted to a Participant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The per share exercise price of each Stock Option shall be not less than the Fair Market Value of the Common Stock subject to the
Stock Option on the date on which the Stock Option is granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Each Stock Option shall become vest and exercisable as provided in the Stock Option Agreement; provided that the Committee shall
have the discretion to accelerate the date as of which any Stock Option shall become exercisable in the event of the Participant&rsquo;s
termination of employment with the Company, or service on the Board or as a Consultant, without cause (as determined by the Board in its
sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>No dividends or dividend equivalents shall be paid with respect to any shares subject to a Stock Option prior to the exercise of
the Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Each Stock Option shall expire, and all rights to purchase shares of Common Stock thereunder shall expire, on the date ten years
after the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.4</FONT><U>Required
Terms and Conditions of ISOs</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the foregoing,
each ISO granted to a Key Employee shall be subject to the following specific rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The aggregate Fair Market Value (determined with respect to each ISO at the time such Option is granted) of the shares of Common
Stock with respect to which ISOs are exercisable for the first time by a Key Employee during any calendar year (under all incentive stock
option plans of the Company and its Subsidiaries) shall not exceed $100,000. If the aggregate Fair Market Value (determined at the time
of grant) of the Common Stock subject to an ISO which first becomes exercisable in any calendar year exceeds the limitation of this Section
5.4(a), so much of the ISO that does not exceed the applicable dollar limit shall be an ISO and the remainder shall be a NSO; but in all
other respects, the original Stock Option Agreement shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Notwithstanding anything herein to the contrary, if an ISO is granted to a Key Employee who owns stock possessing more than 10%
of the total combined voting power of all classes of stock of the Company (or its parent or subsidiaries within the meaning of Section
422(b)(6) of the Code): (i) the purchase price of each share of Common Stock subject to the ISO shall be not less than 110% of the Fair
Market Value of the Common Stock on the date the ISO is granted; and (ii) the ISO shall expire, and all rights to purchase shares of Common
Stock thereunder shall expire, no later than the fifth anniversary of the date the ISO was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>No ISOs shall be granted under the Plan after ten years from the earlier of the date the Plan is adopted or approved by shareholders
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.5</FONT><U>Exercise
of Stock Options</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>A Participant entitled to exercise a Stock Option may do so by delivering written notice to that effect specifying the number of
shares of Common Stock with respect to which the Stock Option is being exercised and any other information the Committee may prescribe.
All notices or requests provided for herein shall be delivered to the Chief Financial Officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Committee in its sole discretion may make available one or more of the following alternatives for the payment of the Stock
Option exercise price: (i) in cash; (ii) in cash received from a broker-dealer to whom the Participant has submitted an exercise notice
together with irrevocable instructions to deliver promptly to the Company the amount of sales proceeds from the sale of the shares subject
to the Stock Option to pay the exercise price; (iii) by directing the Company to withhold such number of shares of Common Stock otherwise
issuable in connection with the exercise of the Stock Option having an aggregate Fair Market Value equal to the exercise price; (iv) by
delivering previously acquired shares of Common Stock that are acceptable to the Committee and that have an aggregate Fair Market Value
on the date of exercise equal to the Stock Option exercise price; (v) by certifying to ownership by attestation of such previously acquired
shares of Common Stock; or (vi) by combination of any of the foregoing methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee shall have the sole discretion
to establish the terms and conditions applicable to any alternative made available for payment of the Stock Option exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 6.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Stock Awards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.1</FONT><U>Grant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may, in its
discretion, (a) grant shares of Common Stock under the Plan to any Participant without consideration from such Participant or (b) sell
shares of Common Stock under the Plan to any Participant for such amount of cash, Common Stock or other consideration as the Committee
deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.2</FONT><U>Stock
Award Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of Common Stock
granted or sold hereunder shall be subject to such restrictions, conditions and other terms as the Board may determine at the time of
grant or sale, the general provisions of the Plan, the restrictions, terms and conditions of the related Stock Award Agreement, and the
following specific rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Award Agreement shall specify whether the shares of Common Stock are granted or sold to the Participant and such other provisions,
not inconsistent with the terms and conditions of the Plan, as the Committee shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The restrictions to which the shares of Common Stock awarded hereunder are subject shall lapse as provided in Stock Award Agreement;
provided that the Committee shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award
held by a Participant in the event of the Participant&rsquo;s termination of employment with the Company, or service on the Board or as
a Consultant, without cause (as determined by the Committee in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Except as provided in this subsection &copy; and unless otherwise set forth in the related Stock Award Agreement, the Participant
receiving a grant of or purchasing Common Stock pursuant to an Award Agreement shall thereupon be a stockholder with respect to such shares
and shall have the rights of a stockholder with respect to such shares, including the right to vote such shares and to receive dividends
and other distributions paid with respect to such shares; provided that any dividends or other distributions payable with respect to the
Stock Award shall be accumulated and held by the Company and paid to the Participant only upon, and to the extent, the restrictions lapse
in accordance with the terms of the applicable Stock Award Agreement. Any such dividends or other distributions held by the Company attributable
to the portion of a Stock Award that is forfeited shall also be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 7.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Stock Unit Awards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.1</FONT><U>Grant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may, in its
discretion, grant Stock Unit Awards to any Participant. Each Stock Unit subject to the Award shall entitle the Participant to receive,
on the date or the occurrence of an event (including the attainment of performance goals) as described in the Stock Unit Award Agreement,
a share of Common Stock or cash equal to the Fair Market Value of a share of Common Stock on such date or the date of such event as provided
in the Stock Unit Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.2</FONT><U>Stock
Unit Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stock Unit Award shall
be subject to such restrictions, conditions and other terms as the Committee may determine at the time of grant, the general provisions
of the Plan, the restrictions, terms and conditions of the related Stock Unit Award Agreement and the following specific rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Stock Unit Agreement shall specify such provisions, not inconsistent with the terms and conditions of the Plan, as the Committee
shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The restrictions to which the shares of Stock Units awarded hereunder are subject shall lapse as provided in Stock Unit Agreement;
provided that the Committee shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award
held by a Participant in the event of the Participant&rsquo;s termination of employment with the Company, or service on the Board or as
a Consultant, without cause (as determined by the Board in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Except as provided in this subsection (c) and unless otherwise set forth in the Stock Unit Agreement, the Participant receiving
a Stock Unit Award shall have no rights of a stockholder, including voting or dividends or other distributions rights, with respect to
any Stock Units prior to the date they are settled in shares of Common Stock; provided that a Stock Unit Award Agreement may provide that
until the Stock Units are settled in shares or cash, the Participant shall be entitled to receive on each dividend or distribution payment
date applicable to the Common Stock an amount equal to the dividends or other distributions that the Participant would have received had
the Stock Units held by the Participant as of the related record date been actual shares of Common Stock. Such amounts shall be accumulated
and held by the Company and paid to the Participant only upon, and to the extent, the restrictions lapse in accordance with the terms
of the applicable Stock Unit Award Agreement. Such amounts held by the Company attributable to the portion of the Stock Unit Award that
is forfeited shall also be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 8.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>SARs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">8.1</FONT><U>Grant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may grant SARs
to Participants. Upon exercise, an SAR entitles the Participant to receive from the Company the number of shares of Common Stock having
an aggregate Fair Market Value equal to the excess of the Fair Market Value of one share as of the date on which the SAR is exercised
over the exercise price, multiplied by the number of shares with respect to which the SAR is being exercised. The Committee, in its discretion,
shall be entitled to cause the Company to elect to settle any part or all of its obligations arising out of the exercise of an SAR by
the payment of cash in lieu of all or part of the shares it would otherwise be obligated to deliver in an amount equal to the Fair Market
Value of such shares on the date of exercise. Cash shall be delivered in lieu of any fractional shares. The terms and conditions of any
such Award shall be determined at the time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">8.2</FONT><U>SAR
Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Each SAR shall be evidenced by a written SAR Agreement specifying the terms and conditions of the SAR as the Committee may determine,
including the SAR exercise price, expiration date of the SAR, the number of shares of Common Stock to which the SAR pertains, the form
of settlement and such other terms and conditions established by the Committee, in its sole discretion, not inconsistent with the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The per Share exercise price of each SAR shall not be less than 100% of the Fair Market Value of a Share on the date the SAR is
granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Each SAR shall expire and all rights thereunder shall cease on the date fixed by the Committee in the related SAR Agreement, which
shall not be later than the ten years after the date of grant; provided however, if a Participant is unable to exercise an SAR because
trading in the Common Stock is prohibited by law or the Company&rsquo;s insider-trading policy, the SAR exercise date shall be extended
to the date that is 30 days after the expiration of the trading prohibition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Each SAR shall become exercisable as provided in the related SAR Agreement; provided that notwithstanding any other Plan provision,
the Committee shall have the discretion to accelerate the date as of which any SAR shall become exercisable in the event of the Participant&rsquo;s
termination of employment, or service on the Board or as a Consultant, without cause (as determined by the Committee in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>No dividends or dividend equivalents shall be paid with respect to any SAR prior to the exercise of the SAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>A person entitled to exercise an SAR may do so by delivery of a written notice in accordance with procedures established by the
Committee specifying the number of shares of Common Stock with respect to which the SAR is being exercised and any other information the
Committee may prescribe. As soon as reasonably practicable after the exercise of an SAR, the Company shall (i) issue the total number
of full shares of Common Stock to which the Participant is entitled and cash in an amount equal to the Fair Market Value, as of the date
of exercise, of any resulting fractional share, and (ii) if the Committee causes the Company to elect to settle all or part of its obligations
arising out of the exercise of the SAR in cash, deliver to the Participant an amount in cash equal to the Fair Market Value, as of the
date of exercise, of the shares it would otherwise be obligated to deliver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 9.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Change in Control.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.1</FONT><U>Effect
of a Change in Control</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Notwithstanding any of the provisions of the Plan or any outstanding Award Agreement, upon a Change in Control of the Company (as
defined in Section 9.2), the Board is authorized and has sole discretion to provide that (i) all outstanding Awards shall become fully
exercisable, (ii) all restrictions applicable to all Awards shall terminate or lapse and (iii) performance goals applicable to any Awards
shall be deemed satisfied at the highest level, as applicable, in order that Participants may realize the benefits thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>In addition to the Board&rsquo;s authority set forth in Section 3, upon such Change in Control of the Company, the Board is authorized
and has sole discretion as to any Award, either at the time such Award is granted hereunder or any time thereafter, to take any one or
more of the following actions: (i) provide for the purchase of any outstanding Stock Option, for an amount of cash equal to the difference
between the exercise price and the then Fair Market Value of the Common Stock covered thereby had such Stock Option been currently exercisable;
(ii) make such adjustment to any such Award then outstanding as the Board deems appropriate to reflect such Change in Control; and (iii)
cause any such Award then outstanding to be assumed by the acquiring or surviving corporation after such Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.2</FONT><U>Definition
of Change in Control</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Change in Control&rdquo;
of the Company shall be deemed to have occurred if at any time during the term of an Award granted under the Plan any of the following
events occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>any Person (other than the Company, a trustee or other fiduciary holding securities under an employee benefit plan of the Company,
or a corporation owned directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership
of shares of Common Stock of the Company) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing
30% or more of the combined voting power of the Company&rsquo;s then outstanding securities entitled to vote generally in the election
of directors (&ldquo;Person&rdquo; and &ldquo;Beneficial Owner&rdquo; being defined in Rule 13d-3 of the General Rules and Regulations
of the Exchange Act);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>the Company is party to a merger, consolidation, reorganization or other similar transaction with another corporation or other
Person unless, following such transaction, more than 50% of the combined voting power of the outstanding securities of the surviving,
resulting or acquiring corporation or Person or its parent entity entitled to vote generally in the election of directors (or Persons
performing similar functions) is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities
who were the beneficial owners of the Company&rsquo;s outstanding securities entitled to vote generally in the election of directors immediately
prior to such transaction, in substantially the same proportions as their ownership, immediately prior to such transaction, of the Company&rsquo;s
outstanding securities entitled to vote generally in the election of directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>the election to the Board, without the recommendation or approval of two-thirds of the incumbent Board, of the lesser of: (i) three
Directors; or (ii) Directors constituting a majority of the number of Directors of the Company then in office; provided, however, that
Directors whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited
to a consent solicitation, relating to the election of Directors of the Company will not be considered as incumbent members of the Board
for purposes of this Section; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>there is a complete liquidation or dissolution of the Company, or the Company sells all or substantially all of its business and/or
assets to another corporation or other Person unless, following such sale, more than 50% of the combined voting power of the outstanding
securities of the acquiring corporation or Person or its parent entity entitled to vote generally in the election of directors (or Persons
performing similar functions) is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities
who were the beneficial owners of the Company&rsquo;s outstanding securities entitled to vote generally in the election of directors immediately
prior to such sale, in substantially the same proportions as their ownership, immediately prior to such sale, of the Company&rsquo;s outstanding
securities entitled to vote generally in the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In no event, however, shall
a Change in Control be deemed to have occurred, with respect to a Participant, if that Participant is part of a purchasing group which
consummates the Change in Control transaction. A Participant shall be deemed &ldquo;part of a purchasing group&rdquo; for purposes of
the preceding sentence if the Participant is an equity participant or has agreed to become an equity participant in the purchasing company
or group (except for (a) passive ownership of less than 3% of the shares of the purchasing company; or (b) ownership of equity participation
in the purchasing company or group which is otherwise not deemed to be significant, as determined prior to the Change in Control by a
majority of the disinterested Directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 10.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Payment of Taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>In connection with any Award, and as a condition to the issuance or delivery of any shares of Common Stock to the Participant in
connection therewith, the Company shall require the Participant to pay the Company the minimum amount of federal, state, local or foreign
taxes required to be withheld, and in the Company&rsquo;s sole discretion, the Company may permit the Participant to pay the Company up
to the maximum individual statutory rate of applicable withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Company in its sole discretion may make available one or more of the following alternatives for the payment of such taxes:
(i) in cash; (ii) in cash received from a broker-dealer to whom the Participant has submitted notice together with irrevocable instructions
to deliver promptly to the Company the amount of sales proceeds from the sale of the shares subject to the Award to pay the withholding
taxes; (iii) by directing the Company to withhold such number of shares of Common Stock otherwise issuable in connection with the Award
having an aggregate Fair Market Value equal to the minimum amount of tax required to be withheld; (iv) by delivering previously acquired
shares of Common Stock of the Company that are acceptable to the Board that have an aggregate Fair Market Value equal to the amount required
to be withheld; or (v) by certifying to ownership by attestation of such previously acquired shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Committee shall have the sole discretion to
establish the terms and conditions applicable to any alternative made available for payment of the required withholding taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 11.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Postponement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may postpone
any grant or settlement of an Award or exercise of a Stock Option or SAR for such time as the Board in its sole discretion may deem necessary
in order to permit the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>to effect, amend or maintain any necessary registration of the Plan or the shares of Common Stock issuable pursuant to an Award,
including upon the exercise of a Stock Option or SAR, under the Securities Act of 1933, as amended, or the securities laws of any applicable
jurisdiction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>to permit any action to be taken in order to (i) list such shares of Common Stock on a stock exchange if shares of Common Stock
are then listed on such exchange or (ii) comply with restrictions or regulations incident to the maintenance of a public market for its
shares of Common Stock, including any rules or regulations of any stock exchange on which the shares of Common Stock are listed; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>to determine that such shares of Common Stock and the Plan are exempt from such registration or that no action of the kind referred
to in (b)(ii) above needs to be taken; and the Company shall not be obligated by virtue of any terms and conditions of any Award or any
provision of the Plan to sell or issue shares of Common Stock in violation of the Securities Act of 1933 or the law of any government
having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any such postponement shall not extend the term
of an Award and neither the Company nor its Directors or officers shall have any obligation or liability to a Participant, the Participant&rsquo;s
successor or any other person with respect to any shares of Common Stock as to which the Award shall lapse because of such postponement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 12.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Nontransferability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awards granted under the Plan, and any rights
and privileges pertaining thereto, may not be transferred, assigned, pledged or hypothecated in any manner, or be subject to execution,
attachment or similar process, by operation of law or otherwise, other than by will or by the laws of descent and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 13.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Delivery of Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares of Common Stock issued pursuant to a Stock
Award, the exercise of a Stock or SAR or the settlement of a Stock Unit Award shall be represented by stock certificates or on a non-certificated
basis, with the ownership of such shares by the Participant evidenced solely by book entry in the records of the Company&rsquo;s transfer
agent; provided, however, that upon the written request of the Participant, the Company shall issue, in the name of the Participant, stock
certificates representing such shares of Common Stock.&nbsp; Notwithstanding the foregoing, shares granted pursuant to a Stock Award shall
be held by the Secretary of the Company until such time as the shares are forfeited or settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 14.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Termination or Amendment of Plan and Award Agreements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">14.1</FONT><U>Termination
or Amendment of Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Except as described in Section 14.3 below, the Board may terminate, suspend, or amend the Plan, in whole or in part, from time
to time, without the approval of the stockholders of the Company, unless such approval is required by applicable law, regulation or rule
of any stock exchange on which the shares of Common Stock are listed. No amendment or termination of the Plan shall adversely affect the
right of any Participant under any outstanding Award in any material way without the written consent of the Participant, unless such amendment
or termination is required by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed.
Subject to the foregoing, the Committee may correct any defect or supply an omission or reconcile any inconsistency in the Plan or in
any Award granted hereunder in the manner and to the extent it shall deem desirable, in its sole discretion, to effectuate the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Board shall have the authority to amend the Plan to the extent necessary or appropriate to comply with applicable law, regulation
or accounting rules in order to permit Participants who are located outside of the United States to participate in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">14.2</FONT><U>Amendment
of Award Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee shall have the
authority to amend any Award Agreement at any time; provided however, that no such amendment shall adversely affect the right of any Participant
under any outstanding Award Agreement in any material way without the written consent of the Participant, unless such amendment is required
by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">14.3</FONT><U>No
Repricing of Stock Options</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
and except as described in Section 4.3, there shall be no amendment to the Plan or any outstanding Stock Option Agreement or SAR Agreement
that results in the repricing of Stock Options or SARs without stockholder approval. For this purpose, repricing includes (i) a reduction
in the exercise price of the Stock Option or SARs or (ii) the cancellation of a Stock Option in exchange for cash, Stock Options or SARs
with an exercise price less than the exercise price of the cancelled Options or SARs, other Awards or any other consideration provided
by the Company, but does not include any adjustment described in Section 4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 15.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>No Contract of Employment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the adoption of the
Plan nor the grant of any Award under the Plan shall be deemed to obligate the Company or any Subsidiary to continue the employment or
service of any Participant for any particular period, nor shall the granting of an Award constitute a request or consent to postpone the
retirement date of any Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 16.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Applicable Law.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All questions pertaining to
the validity, construction and administration of the Plan and all Awards granted under the Plan shall be determined in conformity with
the laws of the State of Nevada, without regard to the conflict of law provisions of any state, and, in the case of Incentive Stock Options,
Section 422 of the Code and regulations issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap">Section 17.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Effective Date and Term of Plan.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">17.1</FONT><U>Effective
Date</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>The Plan </FONT>as amended and restated <FONT STYLE="font-size: 10pt">has been adopted by the Board, and is effective, as of April
6, 2020, subject to the approval of the Plan by the stockholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>In the event the Plan is not approved by stockholders of the Company within 12 months of the date hereof, the Plan </FONT>as amended
and restated <FONT STYLE="font-size: 10pt">shall have no effect, and the Plan as in effect prior to August 9, 2023 shall continue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">17.2</FONT><U>Term
of Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything to
the contrary contained herein, no Awards shall be granted on or after April 6, 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cnsp-20240430.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaqJ6aPty552GYkxvmR/fUk6DyAjL0PIdSyLxodWcQQE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:CNSP="http://cnspharma.com/20240430" elementFormDefault="qualified" targetNamespace="http://cnspharma.com/20240430">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cnspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20240430_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20240430_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cnsp-20240430_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cnsp-20240430_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cnspharma.com/role/Cover" xlink:href="cnsp-20240430.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cnspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140147291908464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CNS Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001729427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2318545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 West Loop South<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">946-9185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNSP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( $>#HU@'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 1X.C
M6'8ZX#OO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ 1X.C6)E<G",0!@  G"<  !,              ( !
MS0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !'@Z-8@K>2=JP$
M  !L$@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ 1X.C6)^@&_"Q @  X@P   T              ( !
M\ P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !'@Z-8EXJ[',     3 @
M"P              @ ',#P  7W)E;',O+G)E;'-02P$"% ,4    " !'@Z-8
MJL0B%C,!   B @  #P              @ &U$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ 1X.C6"0>FZ*M    ^ $  !H              ( !%1(
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 1X.C6&60
M>9(9 0  SP,  !,              ( !^A(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  1!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cns_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cnspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cns_8k.htm">cns_8k.htm</File>
    <File>cnsp-20240430.xsd</File>
    <File>cnsp-20240430_lab.xml</File>
    <File>cnsp-20240430_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cns_8k.htm": {
   "nsprefix": "CNSP",
   "nsuri": "http://cnspharma.com/20240430",
   "dts": {
    "inline": {
     "local": [
      "cns_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "cnsp-20240430.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cnsp-20240430_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cnsp-20240430_pre.xml"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://cnspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-04-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001683168-24-002961-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-24-002961-xbrl.zip
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M!I_P@/-:DY,W%RPZ\$7L&/V>-H[@&G((9RF\KL27^C7+I\'%WDM07,8@KYA
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M1FU]OW>\'YQZ.!KR[89)D2E'A;#FM#* ]-$S\<:=3)FWZ*-( W/<O1.[B],
MPS]5A\Y <B8R)]R">E4U%L@6-)(9_A23S\/^.!11-A6W6ZF!ACS%3!?$X'C^
M[#A&_GTEBK+?\\9&CS0J4MKIP0/BIRTEW)(2FN&C\RS=^Y\*9C22*.<6<$?G
MGE5R1VO/=S#I[2;?<I-U+,J*LX^:+;6[1CWN8T%\N.G67^?Q.8+;(6)7,Z M
MT.&;MNQ%<\LLBKL1.5P:&+[=AUONP\O&/A GZO=.9ZB82W9$?T(KO5-WO#C]
MU,8=B2&RJ496ODM&9+L53>,M#Z*PF/@\M-][N050?,,6O^K<XAIDL+ES'=OD
MB[CGV]WY!K3?0=?N-%42HZJW:[L<!O#4FUMK*-OMN^7V'79MG\52WB5O#%YL
M=^\;=N^HN7O&>&L-J0=(=Z!KP*(S5MJU_R1K*QS+X_P.]3?CKD&:)D%VG0H*
M\Y'O3A0%V[#/#GZDXP!&H2R*2N6PNHE!@K0<A"*JQ!#MD>,IK=O>/UCZQ_'J
MTC].%;S,X%DV,P/D#FCOV,U@N%09C(S"0X);M\-\B\4T&:$VR\* %!V_NUF.
M1E(&HFIRB1DYR"^0AX3 #,KK#(3+="@L")Q=]^A 0\QE,>('*U:7@II@_%BQ
M#TT(8I/6U.]YF.9/52*"P^?#O6/'_G6CWP/X7C$U ^E$1]TU3-B&%^XZ5^U>
M4H!NS$NY$[)Q(FJG53G)<I()UA%Y%S1TWQDX]-^C5QC"?4@>M1/NKDQ27/HD
M#:2$N:8(> /B*Z)<<((5$[FA$]K46L*IFV***H+-_0 5$HA]ROGC%K.<T[^8
MJUXJ5L+YH@R9 X:BS *=U)=/.6UVBO%!\CZ'^AZ^1'R92050(R=YRR7>R.1V
MEUZ<4\U 0;K%%Y%'R-%4J!=#!DG"(ZB3K6[0;\;._T3">M)EL"ZH$N4R4I\X
M(1$OC[*44X?=#"E8*YZ(T</M()RTW_H ?S*I !Z,6MQ0*&3=5$4Z8"XSE:E/
M*^-X(W%5W&L(GFB7;\5$VTE$&TNSPQ72;*:.>XEAF!F29*G2#IR3E(37>/C&
M%1]8IKX<Y&2A4 IDO#6@!ZWA?!W*SSGV'P\L*H 3%)!@8I&(,87;D -H&8!G
MC0^S.IWPV>,<3#M9C;FT'G,D+H%G74% LQ'8+IA"44^9+S %@N>D'ZHXF\O4
M-""@G2;-,^044;<#7"H!9ZE.2.:U<!HTG\*MB&'*QQAOE*N6;"A9W?MPRR#Q
MCK9(O = XAUMD7@;0&'W)R>C.])MD95[I8I4.18&\G@Y%0-; (H%!$M-KHNC
MY:F6$+$04U2Y$!J$&!2=>((RN-\;J>0&+* B<F-1YYX.R6/BXU'<3,//UB+5
M0ZG?2OS-R4,,6;:T@$G(R0?3Y<F2,F>"_3=/?#\X0\W/FP5>X(U*-7GP_6!2
M*2:G%!6*>6<D-[^'O(,SK"O$$W+1!UI[1IDJ080NH^3JF &J!&3R#ZPG8B01
M:JANAPD4Z+W&K<#?318-5?^I9HA/Q*\)3;-"!\!W2K_QZNCW7'N.&JFXOO)I
M]CV1I/F.%-Y)G5,^G_"=?YSI^)K3@]0RSK(X&(5 /OLX%\S?@G.:MHZ&65NE
M+"M0=W66F)<>!HH!@VHX#=_S?[7,G%SE"2,Z<).F*=(!3Y3.:2[D= @DQM K
M&*JKM$*#$.NI5&VE*$%Z@S*A3(/WJ9,+29<YM_1[YIY?YF!BK"_!/+2?V8'&
MUNNH%.OH:GXL#&B%SK&SL :+1$KE&C/*W ZN<Z3DM%&<AD797"=DWBC0]H'L
M6 ;ZKK>F"W5@;W+&0^W /#KP/$@6&393/WD@-,462,57@CH#TYA$^S3+-9@4
M=1E55BL(S4&UR%7%9EX'.W*7\G/-U- 3!8^DI-M2-.YHK^/GQQ80X6JK4_9[
M%KRO'7WM/C.ELTVQEB'\'S^!Y8-6-F C0?3+C*(6Y!ZT[^EI/Z.NI>OW+ RV
M\78GL![U!<'%(%<B22GGYM#6/1KA7@A3%RO+@\BM4A'F.;H0Z"[S8OW>4)37
M6":BOKRUF9_0ES"QEIFIRH^,]DU'>-A+";3,L>4(K$Y>3/3'<G01-@ZVRIZ)
M?D\=1KK2T5:[_"QM,M$X;H P&BNOK@%1G9 KD])%Z-PJG+XS'7(O:\2_BDXW
MZ2EUSHS6+!GV;/W0QNW4G,F0E(Z1D*42K,I5+-;<;_H08?"GJPN#7[0#5BZL
M$:C *=OP^)+2]:D7'L_*,.GWSBNMH_-Z;Y671Z&\4+ (=RA(S09U(+@X-XIC
M7@KDXZ/(+9M[.CA^^FSP\N @V&$1G8L1@M&9B[]4O_$XF#P"ZE)6%5@\@P,"
M?S6?C?SR>/#LX&!P8&Y5G+=],KZ%(U4VNZFEGK.!@I]W63CU>^JI.J[')2B<
M*0TK+&6AAM.KE%/!C*+"S"+ZBITT#CX"SP=7(*WG%#6]2P8T_'3_^&ZP<=^I
MQV&5D35,T+V)6F*1@!*::PN@)88Z$4FS:@UF:L')&>D4XH8J$0+!C"HX6E18
M)D>MRRLPD^I MG6J<1B0@]1N!G(=?:N&5$F/,4\R2_@9X1=<"IOW%8Y!;T-=
MTBG@@BHS4@<=<)?^"E#:R:>OXWLNC5 F+URE(F0PV7 ,>AD%"9=F2C235D:P
M'YRF\Z[;89+1)"R:Y8.(/($T(R%@4E0 H[9@9D57MR;N>M"SBO*F]5C$E/L]
MPSGM''71;DXSKS_.SONN$H2^4_:SPH %6SJYH.)) 44$!]JPJ'(*06N$RR"H
MN>;KX!0\ZFS/:'<H'@[X;<>R#_R%O\44^R+*Y1"1?DZ-T./]XUVJ="4[Z33,
M:^?32295MB>,,4(3#2^%OR/%A6J$Z9(0Q?P*='NB=[5Y+;DR#/$I7 ![1CJF
MZ41^G GR G1,B$EK=>R0JH!]*TMDZ[J3):XU-=\S:/&I"UJ\4"KKG[2>O'GK
M:,G<@AO^,5I ,/V>HQY[YWV!-FYM^,--**;_6$3,BJW":?A%3JOIS?PF5-A-
MM//"9F$$G1?D*D^%*LM>D%$$3#0*$S#.PCR8BS#O]TPY1$13P<GZST-C^:'7
MD>Q5+IBZ W=&%&Q7BBY_[6K/[0,/2>OSO.#D)1Z%4A5C):?Z@B?@<<<8<DJ)
M,;G -BE4XT>%CL&L_%5%(<.K3++9!X^,LVI8#I:QLJEQQ0B+0#IU[\DW^@0G
M42MZ7W00V1$H'XYL0:' 92I,4PQ3"#(PJ[G*-/Y'I?(]2M#9\19T]@"@L^,M
MZ&P#*&QM74A+"UA7)+B884\J[;R_^,.(AG/X>U<G=+:[=VNI48Y.!HK$AO+^
MM33WO_JH:.TA6$YY<&^UL4SL$>DWRVM5V8([T-B\"6L5R)WQS2I<X&MP-RW!
MS1I=O[<BE:Y&O7I*J%=V:7&AH\6QN_,[5N/6$JIX*U)V.'T-S%HSK37BEI-4
MJYSKY,\)G5.SJQ3VP5:G9]1CF8T%Q;JX6241=S'!4O5P&D/9<'EI[YB!,:I1
MN1^)QQ>HU+V"/F9.EY%!BY%W_-4,X_8,P5)\O[>8Y->5?CI&L<&KPCE\QJ]+
M6%=I0[F$HEH4PK0<ZH[BE9OL6731G;3&&,9;[^SG6W!KA67$7E>E#3YF^3A,
MY5\<OT#??A3.)' #_95*280-D*7^$&.VA&H#/ BF(A\CTA_1UV@#Z_OPCKUJ
MAG^!896-1GC)=*C"(Y3V@<V+"_K@W=SO 1NS29 C)](/O)*_U7 XGBU,+*\B
MC,=TE-DL),B.,#<=9:C"<%HP&GW0BG;#G ]0VPFX9DZ+GV%"G;5GN:3BQ5UI
MVM3+F$,F-(Z"#Q:<#E(RBMM^64O!8,[9[W6T3%0X/V=^E!W)JLKK +48^Z->
M-"4,\?&?91H[C,F$=MJ=RQSB/ FP&.]M'AME)C;O%JGA=X/'16V/:\;0G7O]
M&IC62VA2>]0MGB;:JH7Z"PJ3B7>]]51"///\\DXR>;=EA^,]]?OY*9"GV.5G
MDA; ![JPF0GV(-H:& I[0V5]:@'C2.91-<6%B3:H5L9#H!R?K0[E^+=<]UGW
MSND6UKB\O'[FPAII/3<\]'?AYT$R,EL#_6TG;3_!O]G)D#5QGSTBJM:BFHI]
MX(!4>,=:,N(+"JDBF=LJU+5FAC0->OB@]O0.2ZE15$#7$$%_V?[2SW"2JMR"
MN\!XKR<9B5VJB!$AR@;!#&3CF#%OK$_N36I3N.<]J];/O*"]6Y'29L-\-WKV
MI9OU0D?3/>D$>UV8M=3>C+N1O#2?B;IX\8OS6/V)4FG\+ZF&?*3REIC3C/S>
M>4T5K+.@#W[M]WYO1;LU''496;R.YZ6Q6@S4N2%;Q22&>VBAFZHG*70>-OHK
M2LI),1CA>["H-Y@5.%;VF3EM'TDAQXW3WP4?Z5A^-VSA?]MJ/?F\TLEI\B#,
M6]C.HX7MF-;!+>9JDYL9UN^7<T6>@ZVN K?3E9L3U^:E)G7,QY2G3O:E6SG*
MN\KV1UE;7^MC.4LKC%"?=9X52K/%MB_$/=4I(Q= 6%A=7?E,VG6'DUIGF19O
M5[\W"95_R@I)8D11)!*1Z_XV=+@XTU=!T%";[IRW.UU9\S]V9N[6,GP7)/(2
M"KHMWD%ZOM]0=T!W9Y5N^KOCM3#SV\.SS@"JB:\TK&]TXI$-MPQ(Z^D6I/4
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MF\3G\3,P4$*9J@IG&-4FVYP9L@E9W4^KDN"..I4\*BMX;<,;V!+B8F%+"$-
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M>Y@6P,O4R=D 6Q+HDBM3M">@#4S9*ZXPR@G!LUQ>R42,T6?)!8V52Q%LOFQ
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M]\G77.KDI 18P<)G(HE2(5!<_TF_"-C\[Q23LO5>'Y;J*$YV$I!]96*I&(N
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M3%:+XA[Y2+M=\HF.43(=]A7=!NX]5G";P#?;\+=&8S &7Q/(#U)C2P=PH3F
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M6X>_$BZ#N@%U(KX1SK9&6!6-OWH#E2C\C\7$' \K/.H(_IX)/?\NKJL/:/*
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M?>*8EL5V[IA*$A >-E\=&60$TEHO+"PVF-+/VS1A)(4G(D/EE@6KQ28+#4E
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M"YWJI:A> 5JI9\3**M!OJA*4UV+[_?+ZIFOY26[6F^1?*YP2N>6_4$L#!!0
M   ( $>#HUBC$C<950<  -=7   5    8VYS<"TR,#(T,#0S,%]P<F4N>&UL
MS9Q=<]HX%(;O=V;_@Y>]!@+I?B1-MI/0T&&:-MF0MKM[TQ&V $UDB9'D /]^
M)1M3/BSYY,8GN4B(>?7Q/L>6?6S)%^]6*8^>J=),BLM6KW/2BJB(9<+$[++U
M9=R^&@]&HU:D#1$)X5+0RY:0K7=__?Q39'\N?FFWHR&C/#F/WLNX/1)3^3;Z
M3%)Z'GV@@BIBI'H;?24\<UODD'&JHH%,%YP::K\H&CZ/?NOT^R1JMP'U?J4B
MD>K+PVA;[]R8A3[O=I?+94?(9[*4ZDEW8IG"*AP;8C*]K>UD=;+Y*8I?<":>
MSMVO"=$TLKR$/E]I=MER[6Z:79YVI)IU^R<GO>X_GV['\9RFI,V$XQ;35EG*
MU5)5KG=V=M;-ORVE1\K51/&RC=-NV9UMS?9;%M#O]$2S<YUW[U;&Q.1AKVTF
M\BK<?^U2UG:;VKU^^[376>FD5<+/"2K)Z0.=1NZOC=ZVU5CHQ9RHE+B(==VW
MW8&T>Z3M:EYNKNCTLN54MOK^FY,WIR>N\E_W1&:]L'NF9F[':D7=O887BFHJ
M3.[UUF[8*T)7QNY/-"DK<NV#NV:8<>K-[M*+VF[?RE+;F/U8*#<]*?O"9;S7
M/'<QD =>R_TY)ZUIW)G)YVY"6=?Y=Q]R$#D$^\_WO*&KB3:*Q*:LB9,)Y7G]
MWZWF0-)MH%<EB4=;8W6G]A6'?=J-VI6*(ZD2JBSKLBZBXKU8'>^:&T5W092M
MJ!W/&=^&>:IDZJ.S(2$]'=T%99MHAN:5;3]Q?1AR,JO&>2 !\NQA *UT@T7T
M/=6Q8@O'I0;LGA+(MX_*M\);PYC+8^>!SICKK^N*.^%2MS$\+GB* ,&?8HX4
M0;=($;@2(B/\@2ZDJ@&_KP3R?H/)N\H;$N:_,Z(,57P-(7TD!L+^#1.VQR$2
M[T=%A&:.#P3XL1I(_'?4"P^/1R3DXSGEW"5Q1(#V\BH]$/L?F-C]/E\!^)MG
M=WZWIQ8X^YTB0/Q_OA;\1VZ1(G!/%9.)/:4K /LC,9#Z&29UCT-4WC<B@=+>
M2L'Y#S[L WM(J(=,QX07/1K:;3J,NT(.18Z2<];:1,7^+R4*#'U'#$6.DH;6
M6&P8^"!3:J\SP5'%KX8B1TE ZTPVS/Q&&&;6[J[_YRR=_+AQNL_Z6 5EC))T
M^DRAL"WO- CC'F:$^!XJH8Q1<LV0.13. ^M'$3X2"5U]I.L0Z",IE#1*CAFT
MAX+Z7K&4J/68Q?6#QK$6"ALELPP;1*']2%:CQ+IB4U8\#JR'[BT"98^25H+L
MHH1@)&*I%G+G=O% 9O9X7 ]D$AS2:PI"PX&2;[[ .DI0KI+$XM*;/[=,T%XH
M%)5R\#,BO  $;+X2[/V78>_#L:/DH;4V7PGVTY=A/X5C1\E%:VUB8A_8CW?J
M42X]3Z"]8BARE%RTQB(F\/Q,<Z?NE7QFQ:RH.NI'):#H$5/4L%G4';XXR4/V
M]E()Y8V8KE:;P^1\+[4A_#^VJ+N2K-9#F2,FKB&C3=]@+.+N;EKXIA(=2*!\
M47+52CM-(W415I3X=]]]!10H2@):9:9AGK?2/?N82Q&\'WNL@G)%R21]IIH>
M>-U,8NT]]'>^!L]@0QE6#VTTC/&;8L;V8"#3-!.;>S2>IV(>*10O2OH7M-<P
MZK'D+&:&B=DG>X6H&.'5G*MT4,@HR9[?6,.$[Q5UD:;VLCN?Q^66&JB[Z=0W
M\H;T4.(HN5Z]45SR(ZTSJE[*OZ(4- HH:1_4=-/C#(TS.^RM>_W)HULQXQEE
MCE10UB@IG\]4PVP_RT=%W&J]\3J=2.Y?'E(IA!)&2? "UAJ&O->/:KP'$BA8
ME,RNT@[2F'"SBN=$S*A_]D*U$@H8)=,+F4,;>V>@L7?VPK$7)>/SF4)B6\P-
MMT?4W82S&?&O) L6 *^SP20>L-KT^KU\R8];QZW2O!]#^Z$:NT<*!8ZS1#)D
MKVG46<(,38HN#9D@(K8IU79=FR<[KR\%#0#.&DJ@:93;^]\HYQ^%7(HQ)5H*
MFA27^J$[_-XBT"@@/D.LL8L2@J^29Y:2RB>"*L\QX)%"D2,^._38PYE[64QJ
MWIY[BA=VA(C[2D#!(SY$#)M%FI]FJ.LS>Z;OB2&;'H;X^TI ^2,^4 R;19L_
MKP;VQ#.3X6?F!T(H;<2IL)764""/4\+Y=::9H#HXMAP(H9 1Y[Q66D.!?)-2
M-;.#V@<EEV:^6=L9@NTI (6..+,U:!4'_NK'.O)B_5N0?(4:_'8"1.Q>DUBO
MW8AC-Y&B.).+A"@/]9 >RAUU8:7?:,/D[\R<JMWKI[PS(YNWA28]U)>"1@$E
M786:QCFW[JSD#YY:]W10WHB):94QG#53V82S>,@E"5Z7[\F@?!&ST I;*'BO
MB7A2V<+$ZWLE8TK=XQ.]/=H "1&P FA($//3%Z' N5T@T]0M)I+QTWAN3>N[
MS.3O+[7]"]XT"):#A@9S$2? .-)5D/ZQT(LFU^L'.J7*35-XI"MS;1MZ"E\4
M 8I#XX/Z1B$PAHHP772/?-W:#>X-M<4W[I=["ZO=\C]02P$"% ,4    " !'
M@Z-8,59R_,H!  #Z!0  #               @ $     8VYS7S S,#$N:'1M
M4$L! A0#%     @ 1X.C6$@<M_?R,P  !H0!  P              ( !] $
M &-N<U\Q,# Q+FAT;5!+ 0(4 Q0    ( $>#HUA@,G#^3QT  -+#   *
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2      8 !@!Q 0  F&D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>cns_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cnsp-20240430.xsd" xlink:type="simple"/>
    <context id="AsOf2024-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729427</identifier>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-04-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2024-04-30" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-04-30" id="Fact000005">0001729427</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-04-30" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-04-30" id="Fact000011">2024-04-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-04-30" id="Fact000012">CNS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-04-30" id="Fact000013">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-04-30" id="Fact000014">001-39126</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-04-30" id="Fact000015">82-2318545</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-04-30" id="Fact000016">2100 West Loop South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-04-30" id="Fact000017">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-04-30" id="Fact000018">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-04-30" id="Fact000019">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-04-30" id="Fact000020">77027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-04-30" id="Fact000021">(800)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-04-30" id="Fact000022">946-9185</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-04-30" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-04-30" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-04-30" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-04-30" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-04-30" id="Fact000027">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2024-04-30" id="Fact000028">false</dei:EntityExTransitionPeriod>
    <dei:Security12bTitle contextRef="AsOf2024-04-30" id="Fact000029">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-04-30" id="Fact000030">CNSP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-04-30" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
